比卡鲁胺治疗晚期前列腺癌对血清PSA、f-PSA含量影响  

Change of serum postate specific antigen and free prostate spectific antigen contents in advanced prostate cancer patients treated with bicalutamide

作　　者：蔡振 周华设 

机构地区：[1]上海市利群医院泌尿外科,200333

出　　处：《实用诊断与治疗杂志》2006年第6期401-402,共2页Journal of Practical Diagnosis and Therapy

摘　　要：目的:探讨前列腺癌患者比卡鲁胺治疗后前列腺特异抗原(PSA)、游离前列腺特异抗原与总前列腺特异抗原比值变化的临床意义。方法:测定前列腺癌患者内分泌治疗前及治疗后1,3,6个月血清前列腺特异抗原、游离前列腺特异抗原变化。结果:治疗后1个月与治疗前相比血清前列腺特异抗原下降明显,治疗后6个月较治疗后1个月血清前列腺特异抗原下降亦有显著意义;治疗后患者血清游离前列腺特异抗原水平明显下降。结论:血清游离前列腺特异抗原等可作为判断前列腺癌内分泌治疗效果的标准,比卡鲁胺治疗晚期前列腺癌有较好疗效。Objective To investigate the clinical significance of changes in prostate specific antigen,and changes in proportions of free prostate apecific antigen with total prostate specific antigen （FPSA/PSA） in patients with advanced prostate cancer after treated with bicalutamide. Methods Serum prostate specific antigen and free prostate specific antigen contents were determined before treatment and 1,3,6 months after treatment. Results Serum of prostate specific antigen was greatly decreased 1 month after therapy. The serum prostate spectific antigen was significantly decreased in 6 months compared with that in 1 month after treatment. Serum free prostate specific antigen was obviously decreased in all patients after therapy. Conclusion Serum prostate specific antigen and free prostate specific antigen evaluation is useful in prostate cancer patients undergoing hormonal therapy. Bicalutamide therapy is effective for advanced prostate cancer patients.

关 键 词：前列腺癌 前列腺特异抗原 比卡鲁胺 

分 类 号：R737.25[医药卫生—肿瘤]